Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 81 Records) |
| Query Trace: Disease Progression and MET[original query] |
|---|
| Untangling huge literature to disinter genetic underpinnings of Alzheimer's Disease: A systematic review and meta-analysis. Ageing research reviews 2021 8 71 101421. G N S Hema Sree, Marise V Lakshmi Prasanna, Satish Kshreeraja S, Yergolkar Abhijna Vithal, Krishnamurthy Mamatha, Ganesan Rajalekshmi Saraswathy, Radhika K, Burri Raghunadha |
| Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. JAMA oncology 2021 Aug . Martinelli Erika, Martini Giulia, Famiglietti Vincenzo, Troiani Teresa, Napolitano Stefania, Pietrantonio Filippo, Ciardiello Davide, Terminiello Marinella, Borrelli Carola, Vitiello Pietro Paolo, De Braud Filippo, Morano Federica, Avallone Antonio, Normanno Nicola, Nappi Anna, Maiello Evaristo, Latiano Tiziana, Falcone Alfredo, Cremolini Chiara, Rossini Daniele, Santabarbara Giuseppe, Pinto Carmine, Santini Daniele, Cardone Claudia, Zanaletti Nicoletta, Di Liello Alessandra, Renato Daniela, Esposito Lucia, Marrone Francesca, Ciardiello Fortuna |
| RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. Drug safety 2021 12 45 (1): 45-64. Nadal Ernest, Horinouchi Hidehito, Shih Jin-Yuan, Nakagawa Kazuhiko, Reck Martin, Garon Edward B, Wei Yu-Feng, Kollmeier Jens, Frimodt-Moller Bente, Barrett Emily, Lipkovich Olga, Visseren-Grul Carla, Novello Silv |
| MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC. Thoracic cancer 2022 9 13 (21): 3032-3041. Tyler Logan C, Le Anh T, Chen Nan, Nijmeh Hala, Bao Liming, Wilson Timothy R, Chen David, Simmons Brian, Turner Kristen M, Perusse Dean, Kasibhatla Shailaja, Christiansen Jason, Dudek Arkadiusz Z, Doebele Robert |
| Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series study. Respiratory investigation 2022 9 60 (6): 852-856. Seki Yoshitaka, Yoshida Tatsuya, Kohno Takashi, Masuda Ken, Okuma Yusuke, Goto Yasushi, Horinouchi Hidehito, Yamamoto Noboru, Kuwano Kazuyoshi, Ohe Yuichi |
| Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2). BMC medicine 2022 8 20 (1): 277. Yang Guangjian, Xu Haiyan, Yang Yaning, Zhang Shuyang, Xu Fei, Hao Xuezhi, Li Junling, Xing Puyuan, Hu Xingsheng, Liu Yutao, Wang Lin, Lin Lin, Wang Zhijie, Duan Jianchun, Wang Jie, Wang Y |
| Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer. The Prostate 2022 6 82 (13): 1264-1272. Bray Alexander W, Duan Rong, Malalur Pannaga, Drusbosky Leylah M, Gourdin Theodore S, Hill Elizabeth G, Lilly Michael |
| Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors. Therapeutic advances in medical oncology 2022 6 14 17588359221105022. Xu Ting, Wang Xicheng, Wang Zhenghang, Deng Ting, Qi Changsong, Liu Dan, Li Yanyan, Ji Congcong, Li Jian, Shen L |
| Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study. Therapeutic advances in medical oncology 2022 11 14 17588359221133546. Yu Yongfeng, Ren Yongxin, Fang Jian, Cao Lejie, Liang Zongan, Guo Qisen, Han Sen, Ji Zimei, Wang Ye, Sun Yulan, Chen Yuan, Li Xingya, Xu Hua, Zhou Jianying, Jiang Liyan, Cheng Ying, Han Zhigang, Shi Jianhua, Chen Gongyan, Ma Rui, Fan Yun, Sun Sanyuan, Jiao Longxian, Jia Xiaoyun, Wang Linfang, Lu Puhan, Xu Qian, Luo Xian, Su Weiguo, Lu Sh |
| Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. The Lancet. Respiratory medicine 2023 5 . Shun Lu, Jianying Zhou, Hong Jian, Lin Wu, Ying Cheng, Yun Fan, Jian Fang, Gongyan Chen, Zhihong Zhang, Dongqing Lv, Liyan Jiang, Rong Wu, Xiangming Jin, Xiaodong Zhang, Junhong Zhang, Conghua Xie, Gengyun Sun, Dongning Huang, Jiuwei Cui, Renhua Guo, Zhigang Han, Zhendong Chen, Jin Liang, Wu Zhuang, Xingsheng Hu, Aimin Zang, Yi Zhang, Shundong Cang, Yuanbo Lan, Xi Chen, Laiyu Liu, Xingya Li, Jun Chen, Rui Ma, Yanzhen Guo, Ping Sun, Panwen Tian, Yueyin Pan, Zhe Liu, Peiguo Cao, Lieming Ding, Yang Wang, Xiaobin Yuan, Pengxiang |
| Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA oncology 2023 5 . Stefania Napolitano, Vincenzo De Falco, Giulia Martini, Davide Ciardiello, Erika Martinelli, Carminia Maria Della Corte, Lucia Esposito, Vincenzo Famiglietti, Alessandra Di Liello, Antonio Avallone, Claudia Cardone, Alfonso De Stefano, Vincenzo Montesarchio, Maria Giulia Zampino, Roberto Bordonaro, Mario Scartozzi, Daniele Santini, Massimo Di Maio, Ferdinando De Vita, Lucia Altucci, Francesca Marrone, Fortunato Ciardiello, Teresa Troia |
| Genomic landscape and survival analysis of ctDNA "neo-RAS wild-type" patients with originally RAS mutant metastatic colorectal cancer. Frontiers in oncology 2023 4 13 1160673. Nicolazzo Chiara, Magri Valentina, Marino Luca, Belardinilli Francesca, Di Nicolantonio Federica, De Renzi Gianluigi, Caponnetto Salvatore, De Meo Michela, Giannini Giuseppe, Santini Daniele, Cortesi Enrico, Gazzaniga Pao |
| Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 2023 2 14 (1): 1071. Chmielecki Juliann, Mok Tony, Wu Yi-Long, Han Ji-Youn, Ahn Myung-Ju, Ramalingam Suresh S, John Thomas, Okamoto Isamu, Yang James Chih-Hsin, Shepherd Frances A, Bulusu Krishna C, Laus Gianluca, Collins Barbara, Barrett J Carl, Hartmaier Ryan J, Papadimitrakopoulou Vassili |
| Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature communications 2023 2 14 (1): 1070. Chmielecki Juliann, Gray Jhanelle E, Cheng Ying, Ohe Yuichiro, Imamura Fumio, Cho Byoung Chul, Lin Meng-Chih, Majem Margarita, Shah Riyaz, Rukazenkov Yuri, Todd Alexander, Markovets Aleksandra, Barrett J Carl, Hartmaier Ryan J, Ramalingam Suresh |
| Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study. The Lancet. Haematology 2023 12 11 (1): e51-e61. Catherine Cargo, Elsa Bernard, Tumas Beinortas, Kelly L Bolton, Paul Glover, Helen Warren, Daniel Payne, Rukhsaar Ali, Alesia Khan, Mike Short, Suzan Van Hoppe, Alex Smith, Jan Taylor, Paul Evans, Elli Papaemmanuil, Simon Crou |
| Pulmonary Low Malignant Potential Adenocarcinoma: A Validation of the Proposed Criteria for This Novel Subtype. The American journal of surgical pathology 2023 11 . Alessandra Pittaro, Filippo Crivelli, Giulia Orlando, Francesca Napoli, Vanessa Zambelli, Francesco Guerrera, Simona Sobrero, Marco Volante, Luisella Righi, Mauro Papot |
| Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 11 JCO2300339. Joaquin Mateo, Johann S de Bono, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Mustafa Özgüro?lu, Niven Mehra, Nobuaki Matsubara, Jae Young Joung, Charles Padua, Ernesto Korbenfeld, Jinyu Kang, Helen Marshall, Zhongwu Lai, Alan Barnicle, Christian Poehlein, Natalia Lukashchuk, Maha Hussa |
| Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution. Heliyon 2023 1 8 (12): e12374. Yang Hainan, Wen Lei, Zhao Chao, Chen Jianing, Zhou Zhaoming, Zhou Cheng, Cai Linbo, Zhou Caic |
| Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a MET exon 14 mutation. Personalized medicine 2024 7 1-5. Nicole Conci, Virginia Marchiori, Alessandro Di Federico, Andrea De Giglio, Francesca Sperandi, Barbara Melotti, Francesco Gelsomi |
| Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants. JHEP reports : innovation in hepatology 2024 7 6 (7): 101092. Fernando Bril, Srilaxmi Kalavalapalli, Romina Lomonaco, Reginald Frye, Eddison Godinez Leiva, Kenneth Cu |
| Clinicopathological characteristics and prognosis of synchronous brain metastases from non-small cell lung cancer compared with metachronous brain metastases. Frontiers in oncology 2024 6 14 1400792. Jing Li, Xiaofang Zhang, Ye Wang, Yi Jin, Yingqiu Song, Tianlu Wa |
| Clinical and genetic characteristics of 1672 cases of amyotrophic lateral sclerosis in China: a single-center retrospective study. Journal of neurology 2024 6 . Dongchao Shen, Xunzhe Yang, Di He, Kang Zhang, Shuangwu Liu, Xiaohan Sun, Jinyue Li, Zhengyi Cai, Mingsheng Liu, Xue Zhang, Qing Liu, Liying C |
| Effective treatment of MET exon 14 skipping mutation-positive non-small cell lung cancer using capmatinib following serious maculopapular rash caused by two MET inhibitors: a case report. AME case reports 2024 5 8 42. Fumihiro Kashizaki, Shunsuke Okazaki, Nanami Tsuchiya, Hao Chen, Harumi Koizumi, Kenichi Takahas |
| Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2. JCO precision oncology 2024 4 8 e2300407. Jun Gong, Alain C Mita, Zihan Wei, Heather H Cheng, Edith P Mitchell, John J Wright, S Percy Ivy, Victoria Wang, Robert C Gray, Lisa M McShane, Larry V Rubinstein, David R Patton, P Mickey Williams, Stanley R Hamilton, James V Tricoli, Barbara A Conley, Carlos L Arteaga, Lyndsay N Harris, Peter J O'Dwyer, Alice P Chen, Keith T Flaher |
| [Diagnosis and Risk Stratification of Acute Myeloid Leukemia, Myelodysplasia -Related]. Zhongguo shi yan xue ye xue za zhi 2024 10 32 (5): 1372-1376. Hui Yang, Rui Guo, Yu Shi, Chun Qiao, Yan Wang, Yu-Jie Wu, Hai-Rong Q |
| Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small Cell Lung Cancer - Results from the Drug Rediscovery Protocol. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 10 . Karlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, Birgit S Geurts, Ilse A C Spiekman, Gijs F de Wit, Paul Roepman, Anne M L Jansen, Vincent van der Noort, Egbert F Smit, Ann Hoeben, Lizza E L Hendriks, Michel M Van den Heuvel, Berber Piet, Gerarda J M Herder, Sayed M S Hashemi, Hans Gelderblom, Henk M W Verheul, Emile E Voest, Adrianus J de Lang |
| Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England) 2024 1 13524585231219138. Sebastian Camerlingo, Fernando Rubinstein, Maria Celia Ysrraelit, Jorge Correale, Edgar Carnero Contentti, Juan I Rojas, Liliana Patrucco, Felisa Del Valle Leguizamon, Veronica Tkachuk, Nora Fernandez Liguori, Edgardo Cristiano, Carolina Mainella, Gisela Zanga, Adriana Carra, Mariano Marrodan, Alejandra Diana Martinez, Berenice Anabel Silva, Ricardo Alon |
| Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC). Translational lung cancer research 2024 1 12 (12): 2448-2459. Dae-Ho Choi, Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Se-Hoon L |
| Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases. Heliyon 2025 1 10 (24): e40703. Liqun Li, Zhe Huang, Yangqian Chen, Hongzhi Ma, Xiaoquan Chen, Huan Yan, Haoyue Qin, Yuda Zhang, Xing Zhang, Wenjuan Jiang, Zhan Wang, Lin Zhang, Fanxu Zeng, Zhiguo Zhou, Xingxiang Pu, Nong Yang, Liang Zeng, Yongchang Zha |
| Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2025 1 . Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E Marmarelis, Yuichiro Ohe, Reyes Bernabe Caro, Dong-Wan Kim, Jong-Seok Lee, Sophie Cousin, Eiki Ichihara, Yongsheng Li, Luis Paz-Ares, Akira Ono, Rachel E Sanborn, Naohiro Watanabe, Maria Jose de Miguel, Carole Helissey, Catherine A Shu, Alexander I Spira, Pascale Tomasini, James Chih-Hsin Yang, Yiping Zhang, Enriqueta Felip, Frank Griesinger, Saiama N Waqar, Antonio Calles, Joel W Neal, Christina S Baik, Pasi A Jänne, S Martin Shreeve, Joshua C Curtin, Bharvin Patel, Michael Gormley, Xuesong Lyu, Jun Chen, Pei-Ling Chu, Janine Mahoney, Leonardo Trani, Joshua M Bauml, Meena Thayu, Roland E Knoblauch, Byoung Chul C |
- Page last reviewed:Feb 1, 2024
- Content source: